Related Experiment Video
Updated: Jun 5, 2026
10:10
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
Visual outcome following chemotherapy for progressive optic pathway gliomas
Ben Shofty1, Liat Ben-Sira, Sigal Freedman
1Department of Pediatric Neurosurgery, Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel.
Pediatric Blood & Cancer
|January 18, 2011
Summary
Chemotherapy for optic pathway gliomas (OPG) often fails to preserve vision, with most patients experiencing visual decline. New treatments are urgently needed to improve outcomes for OPG patients.
Area of Science:
- Neuro-oncology
- Ophthalmology
Background:
- Optic pathway gliomas (OPG) are slow-growing tumors often associated with neurofibromatosis type 1.
- Treatment for OPG is typically initiated upon documented clinical or radiological deterioration.
- Vision preservation is a primary challenge in managing OPG due to its indolent nature.
Purpose of the Study:
- To evaluate the visual outcomes of patients with progressive OPG treated with chemotherapy.
- To correlate visual outcomes with radiological imaging findings in OPG patients.
Main Methods:
- Retrospective analysis of 19 patients with progressive OPG who received chemotherapy.
- Neuro-ophthalmological follow-up and radiological imaging assessment.
Main Results:
- Over 4 years of follow-up, 73.6% of patients experienced overall visual deterioration, with 27.7% reaching legal blindness.
- Chemotherapy led to radiological tumor progression in 57.8% of patients, and 78% required second-line treatment.
- No significant correlation was found between radiological tumor growth and visual deterioration.
Conclusions:
- Chemotherapy for progressive OPG is associated with a high rate of visual decline.
- Current chemotherapy regimens are insufficient for effective vision preservation in OPG.
- Development of novel and more effective therapeutic strategies is crucial for OPG patients.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...